Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $127,712.00 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 3,200 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $39.91, for a total transaction of $127,712.00. Following the sale, the insider directly owned 84,515 shares of the company’s stock, valued at $3,372,993.65. The trade was a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Castle Biosciences Stock Up 1.1%

NASDAQ:CSTL opened at $32.75 on Friday. The company’s 50 day moving average is $39.36 and its two-hundred day moving average is $29.72. The company has a market cap of $955.97 million, a PE ratio of -72.78 and a beta of 1.06. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $44.28. The company has a current ratio of 6.47, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CSTL. Farther Finance Advisors LLC boosted its stake in Castle Biosciences by 139,100.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after buying an additional 1,391 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Castle Biosciences by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after buying an additional 297 shares during the period. State of Alaska Department of Revenue purchased a new stake in shares of Castle Biosciences during the 3rd quarter valued at $35,000. CWM LLC increased its holdings in shares of Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after buying an additional 853 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of Castle Biosciences by 63.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after buying an additional 976 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CSTL shares. KeyCorp reissued an “overweight” rating and issued a $50.00 price objective on shares of Castle Biosciences in a report on Thursday, January 29th. Guggenheim upped their price target on Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Lake Street Capital lifted their price objective on shares of Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. BTIG Research upped their price target on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Castle Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.14.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.